AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

Subjects

Subjects :

Cancer Research
Oncology
Hematology

Details

ISSN :

21522650

Volume :

22

Database :

OpenAIRE

Journal :

Clinical Lymphoma Myeloma and Leukemia

Accession number :

edsair.doi...........378f36a9d79a8130bc59e00dcb3445a6